Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Cancer Discov. 2019 Jul 23;9(10):1438–1451. doi: 10.1158/2159-8290.CD-19-0393

Figure 2. Frequency of recurrent histone missense mutations in cancer.

Figure 2.

The cBioPortal was queried to determine the frequency of histone mutations in cancer patient samples at each primary site. (A) The frequency for any of the eighteen most significantly recurring histone missense mutations (Z score > 2) in each primary cancer site. (B) The frequency of missense mutations at either H2B glutamate 76 (H2B-E76), H4 aspartate (H4-D68) or H4 arginine (H4-R92), which destabilizes the histone octamer at a specific structural region, in cancers at each primary site. (C) The co-occurrence of the H2B-E76K mutation with mutations in the most common oncogenes found in each cancer type (for cancers with 3 or more patients with H2B-E76K) was assessed by a randomization test through 10,000 rounds of randomization.